

Overview oral presentations and posters during the ESTRO-congres 2010

Oral presentations:

Reduced boost volume irradiation in the posterior fossa for average-risk medulloblastoma: patterns of relapse. G. Janssens *et al.*

Acute toxicity profile and compliance to ARCON for T2-4 laryngeal cancer: results of a phase III randomized trial. G. Janssens *et al.*

Outcome after ARCON for clinical stage T2-4 laryngeal cancer: early results of a phase III randomized trial. J. Kaanders *et al.*

Spinal cord tolerance: radiosurgery and retreatment. A. van der Kogel *et al.*

Expression of the EGFR-PI3-K/AKT pathway in patients with head and neck squamous cell carcinoma. M. Nijkamp *et al.*

Predictive value of hypoxia-related markers in head and neck cancer treated with ARCON. S. Rademakers *et al.*

Can FDG-PET predict radiation treatment outcome in head and neck cancer? D. Schinagl *et al.*

FLT-PET for detection of early treatment response in cervical lymph node metastases of head and neck tumours. E. Troost *et al.*

Oral presentations in collaboration

Preclinical evaluation and validation of [18F]HX4, a novel and promising hypoxia marker for PET imaging. L. Dubois (Maastricht), J. Bussink *et al.*

Simulation of the influence of acute hypoxia on dynamic [18F]-FMISO PET data. D. Moennich (Tübingen), E. Troost *et al.*

Posters

Microenvironmental consequences and growth delay of radiotherapy and EGFR-inhibition in human tumor xenografts. J. Bussink *et al.*

Homogeneous scalp irradiation with multicatheter mask-based HDR-brachytherapy. A. Hoffmann *et al.*

There is no additional role for FLT-ET/CT scan in paediatric brainstem tumors. G. Janssens *et al.*

The developments in prostate cancer treatment with external beam radiotherapy and the introduction of moderate hypo-fractionation in Nijmegen, the Netherlands. G. McColl *et al.*

IMRT with daily intra-fractionally modulated junction(s) for cranio-spinal irradiation. M. Kusters *et al.*

Predictive value of CAIX and Ki-67 in patients with laryngeal cancer treated with ARCON. S. Rademakers *et al.*

Long-term outcome and morbidity after treatment with moderate hypofractionated radiotherapy and endorectal balloon for prostate cancer. H. Rütten *et al.*

Posters in collaboration

Identification of residual metabolic-active areas within NSCLC tumours using a pre-therapy FDG-PET-CT scan: a prospective validation. H. Aerts (Maastricht), J. Bussink *et al.*